Company Overview and News
Elysium Resources Ltd (ASX:EYM) is preparing to reveal details of a significant discovery at one of the Hardey prospects, and the ASX has granted the company a trading halt to prepare.
Elysium has announced it has made an agreement with Hardey to purchase 100 per cent of the company, which comprises five gold and base metal projects in the Pilbara region of Western Australia. The five projects are Bellary, Hamersley, Cheel, Elsie and Grace projects. The first four are located within the Fortescue Group of rocks, while the latter is located in Paterson Province.
Elysium Resources Ltd's (ASX:EYM) shares have rocketed 113% higher to $0.017 in morning trade, with 78 million changing hands.
Elysium Resources Ltd (ASX:EYM) has been granted a trading halt by the ASX this morning, pending details of an acquisition.
Realm Resources Ltd (ASX:RRP) Elysium Resources Ltd (ASX:EYM) have been granted trading halt by the ASX this morning, which will remain in place until Tuesday 18th July 2018, or earlier if announcements are made to the market.
Elysium Resources (ASX:EYM) has been granted a trading halt by the ASX, pending an update from the Burraga copper-gold project, which is located in the world-class minerals province of the East Lachlan Fold Belt.
The halt will remain in place until the opening of trade on Thursday 15th December 2016, or earlier if an announcement is made to the market.
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Elysium Resources Ltd (ASX:EYM) has been granted a trading halt by the ASX, pending details of a capital raising. The halt will remain in place until the opening of trade on Tuesday 20th September 2016, or earlier if an announcement is made to the market.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...